Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 131 Total
GTBP - GT Biopharma Inc - Stock Price Chart
TickerGTBP [NASD]
CompanyGT Biopharma Inc
CountryUSA
IndustryBiotechnology
Market Cap11.34MEPS (ttm)-7.04
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y70.75%
P/S-EPS next 5Y-
P/B2.14EPS Q/Q-841.65%
Dividend-Sales Q/Q-
Insider Own10.42%Inst Own89.93%
Insider Trans0.00%Inst Trans-86.58%
Short Float0.48%EarningsMay 15/a
Analyst Recom1.00Target Price150.00
Avg Volume11.02K52W Range2.95 - 16.11
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.
FFIE - Faraday Future Intelligent Electric Inc - Stock Price Chart
TickerFFIE [NASD]
CompanyFaraday Future Intelligent Electric Inc
CountryUSA
IndustryAuto Manufacturers
Market Cap68.91MEPS (ttm)-67.45
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S125.29EPS next 5Y-
P/B0.07EPS Q/Q59.02%
Dividend-Sales Q/Q-
Insider Own12.00%Inst Own3.35%
Insider Trans0.00%Inst Trans-80.44%
Short Float96.78%EarningsNov 13/a
Analyst Recom3.00Target Price2400.00
Avg Volume124.09M52W Range0.04 - 117.36
Faraday Future Intelligent Electric, Inc. is an emerging growth company, which manufactures electric vehicles. The company was founded by Jia Yueting in May 2014 and is headquartered in Gardena, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aydt MatthiasGlobal Chief Exec. OfficerDec 21 '23Buy100.0011001Dec 27 05:23 PM
Chen XuefengGlobal Chief Exec. OfficerJun 16 '23Buy100.0011001Jun 20 09:39 PM
SCPX - Scorpius Holdings Inc. - Stock Price Chart
TickerSCPX [AMEX]
CompanyScorpius Holdings Inc.
CountryUSA
IndustryBiotechnology
Market Cap5.73MEPS (ttm)-1.74
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y22.72%
P/S0.82EPS next 5Y-
P/B0.13EPS Q/Q56.43%
Dividend-Sales Q/Q5966.34%
Insider Own11.43%Inst Own6.36%
Insider Trans0.00%Inst Trans-22.62%
Short Float0.79%EarningsApr 29/b
Analyst Recom1.00Target Price8.00
Avg Volume3.53M52W Range0.07 - 0.88
Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.
NKGN - NKGen Biotech Inc - Stock Price Chart
TickerNKGN [NASD]
CompanyNKGen Biotech Inc
CountryUSA
IndustryBiotechnology
Market Cap36.66MEPS (ttm)-4.10
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-989.64%
Dividend-Sales Q/Q-
Insider Own58.03%Inst Own8.08%
Insider Trans0.01%Inst Trans14.32%
Short Float5.83%Earnings-
Analyst Recom-Target Price-
Avg Volume3.60M52W Range0.78 - 12.88
Today 08:05AM NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease (GlobeNewswire) +45.54%
May-16-24 08:05AM NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition (GlobeNewswire)
Apr-29-24 08:00AM NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinsons Disease (GlobeNewswire)
Apr-25-24 04:05PM NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit (GlobeNewswire) +15.79%
Apr-24-24 04:45PM NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.57%
Apr-18-24 04:05PM NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit (GlobeNewswire) -16.50%
Apr-16-24 11:53PM NKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023 (InvestorPlace)
Apr-11-24 08:05AM NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs (GlobeNewswire)
Mar-25-24 04:05PM NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference (GlobeNewswire) -6.90%
Mar-06-24 07:52AM Why Is NKGen Biotech (NKGN) Stock Up 62% Today? (InvestorPlace) +112.30%
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Song Paul Y.Chief Executive OfficerDec 07 '23Buy3.2976250171,121Dec 07 05:23 PM
Song Paul Y.Chief Executive OfficerDec 06 '23Buy3.3275250171,045Dec 07 05:23 PM
Song Paul Y.Chief Executive OfficerDec 05 '23Buy3.33105350170,969Dec 05 03:51 PM
Graf James AInterim CFODec 04 '23Buy3.194501,436693Dec 05 03:50 PM
Song Paul Y.Chief Executive OfficerDec 04 '23Buy3.07163500170,864Dec 05 03:51 PM
REKR - Rekor Systems Inc - Stock Price Chart
TickerREKR [NASD]
CompanyRekor Systems Inc
CountryUSA
IndustrySoftware - Infrastructure
Market Cap151.06MEPS (ttm)-0.71
P/E-EPS this Y32.64%
Forward P/E-EPS next Y68.04%
PEG-EPS past 5Y-10.32%
P/S3.92EPS next 5Y-
P/B2.75EPS Q/Q-0.91%
Dividend-Sales Q/Q58.09%
Insider Own6.03%Inst Own57.30%
Insider Trans0.00%Inst Trans-3.69%
Short Float14.43%EarningsMay 15/a
Analyst Recom1.00Target Price4.50
Avg Volume1.29M52W Range1.24 - 4.15
Rekor Systems, Inc. is a technology company, which engages in the provision of roadway intelligence and data-driven mobility insights. It offers comprehensive, continuous, and real-time roadway intelligence by leveraging artificial intelligence (AI), machine learning, and holistic data to support the intelligent infrastructure for smart mobility. The company was founded by James K. McCarthy on February 6, 2017 and is headquartered in Columbia, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BERMAN ROBERT ALANChief Executive OfficerAug 25 '23Buy3.4510,00034,4551,135,219Aug 28 07:03 AM
BERMAN ROBERT ALANChief Executive OfficerAug 18 '23Option Exercise1.25100,000125,0001,125,219Aug 22 07:29 AM
Arctis Global LLC10% OwnerAug 18 '23Buy3.11100,000310,8009,647,491Aug 18 04:38 PM
BERMAN ROBERT ALANChief Executive OfficerAug 18 '23Buy3.1425,00078,4251,025,219Aug 22 07:29 AM
Arctis Global LLC10% OwnerAug 17 '23Buy2.96150,000443,3858,307,591Aug 18 04:38 PM
HIMS - Hims & Hers Health Inc - Stock Price Chart
TickerHIMS [NYSE, RUT]
CompanyHims & Hers Health Inc
CountryUSA
IndustryHousehold & Personal Products
Market Cap4.09BEPS (ttm)-0.02
P/E-EPS this Y253.25%
Forward P/E44.76EPS next Y152.07%
PEG-EPS past 5Y-
P/S4.26EPS next 5Y-
P/B11.84EPS Q/Q199.79%
Dividend-Sales Q/Q45.81%
Insider Own32.29%Inst Own47.18%
Insider Trans-4.18%Inst Trans4.52%
Short Float12.64%EarningsMay 06/a
Analyst Recom1.92Target Price16.33
Avg Volume6.66M52W Range5.65 - 17.16
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pendarvis ChristianeDirectorMay 13 '24Sale12.334,00049,32011,210May 14 04:18 PM
Boughton SoleilChief Legal OfficerMay 13 '24Sale12.332,50330,862159,357May 14 04:17 PM
Carroll Patrick HarrisonChief Medical OfficerMay 09 '24Sale13.0010,000130,000173,880May 13 04:21 PM
Baird MelissaChief Operating OfficerMay 03 '24Option Exercise0.4011,7504,700550,682May 03 06:38 PM
Baird MelissaChief Operating OfficerMay 03 '24Sale11.6411,750136,826538,932May 03 06:38 PM
CMCM - Cheetah Mobile Inc ADR - Stock Price Chart
TickerCMCM [NYSE]
CompanyCheetah Mobile Inc ADR
CountryChina
IndustryInternet Content & Information
Market Cap58.14MEPS (ttm)-2.89
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.61EPS next 5Y-5.39%
P/B0.17EPS Q/Q-671.55%
Dividend-Sales Q/Q-31.83%
Insider Own0.32%Inst Own1.26%
Insider Trans0.00%Inst Trans-1.91%
Short Float0.48%Earnings-
Analyst Recom5.00Target Price1.54
Avg Volume55.76K52W Range1.64 - 5.20
Cheetah Mobile, Inc. is a holding company, which engages in the provision of Internet and mobile security software. It operates through the Internet Business and AI and Others segments. The Internet Business segment provides online advertising, VIP membership and software subscriptions, and game-related services. The AI and Others segment focuses on advertising agency services, multi-cloud management services, and the sale of AI hardware products and technical consulting services. The company was founded by Sheng Fu on July 30, 2009 and is headquartered in Beijing, China.
BCAN - BYND Cannasoft Enterprises Inc - Stock Price Chart
TickerBCAN [NASD]
CompanyBYND Cannasoft Enterprises Inc
CountryIsrael
IndustrySoftware - Infrastructure
Market Cap4.65MEPS (ttm)-109.32
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S6.45EPS next 5Y-
P/B1.38EPS Q/Q-1725.91%
Dividend-Sales Q/Q-26.33%
Insider Own16.31%Inst Own15.11%
Insider Trans0.00%Inst Trans-
Short Float20.57%Earnings-
Analyst Recom-Target Price-
Avg Volume1.96M52W Range0.65 - 687.80
BYND Cannasoft Enterprises, Inc. develops, markets and sells a proprietary client relationship management software known as Benefit CRM and Cannabis CRM platform. It also develops the EZ-G device, a patent-pending device that, combined with proprietary software. The company was founded on March 29, 2021 and is headquartered in Kiryat Motzkin, Israel.
DYN - Dyne Therapeutics Inc - Stock Price Chart
TickerDYN [NASD, RUT]
CompanyDyne Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap2.78BEPS (ttm)-3.97
P/E-EPS this Y21.41%
Forward P/E-EPS next Y-6.98%
PEG-EPS past 5Y-106.26%
P/S-EPS next 5Y-
P/B6.25EPS Q/Q-3.25%
Dividend-Sales Q/Q-
Insider Own34.22%Inst Own82.59%
Insider Trans-10.69%Inst Trans-3.15%
Short Float18.04%EarningsMay 02/a
Analyst Recom1.00Target Price41.89
Avg Volume1.24M52W Range6.40 - 30.27
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McNeill JonathanChief Business OfficerMay 16 '24Sale28.272,77478,420136,634May 17 09:03 PM
HIGH SUSANNA GATTIChief Operating OfficerMay 16 '24Sale28.272,73877,402154,062May 17 09:05 PM
Beskrovnaya OxanaChief Scientific OfficerMay 16 '24Sale28.272,70576,469149,647May 17 09:07 PM
Scalzo Richard WilliamSVP, Head of Finance & Admin.May 16 '24Sale28.272,58873,162116,695May 17 09:04 PM
Farwell WildonChief Medical OfficerMay 16 '24Sale28.272,38167,310148,179May 17 09:06 PM
OSG - Overseas Shipholding Group, Inc. - Stock Price Chart
TickerOSG [NYSE, RUT]
CompanyOverseas Shipholding Group, Inc.
CountryUSA
IndustryOil & Gas Midstream
Market Cap606.50MEPS (ttm)0.83
P/E10.13EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y38.38%
P/S1.33EPS next 5Y-
P/B1.66EPS Q/Q36.99%
Dividend1.43%Sales Q/Q3.26%
Insider Own29.33%Inst Own54.18%
Insider Trans-1.22%Inst Trans5.05%
Short Float0.84%EarningsMay 10/b
Analyst Recom-Target Price-
Avg Volume332.50K52W Range3.59 - 7.00
Overseas Shipholding Group, Inc. engages in the provision of energy transportation services for crude oil and petroleum products in the U.S. Flag trade. It operates Articulated Tug Barges (ATB), lightering ATBs, shuttle tankers, Medium Range (MR) tankers, and non-Jones Act MR tankers that participate in the maritime security program. The company was founded in 1948 and is headquartered in Tampa, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Norton Samuel HPresident and CEOMay 15 '24Sale6.7450,000336,9752,457,479May 15 05:36 PM
Norton Samuel HPresident and CEOApr 16 '24Sale5.9229,663175,7122,507,479Apr 16 06:01 PM
Norton Samuel HPresident and CEOApr 15 '24Sale5.9820,337121,7052,537,142Apr 16 06:01 PM
Mote DamonVP & Chief Admin OfficerMar 22 '24Option Exercise0.0070,1350414,785Mar 26 09:36 PM
Norton Samuel HPresident and CEOMar 22 '24Option Exercise0.00338,15602,605,829Mar 26 09:40 PM
1234561014